184 related articles for article (PubMed ID: 34304603)
1. FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
Tennenbaum J; Groh M; Venditti L; Campos-Gazeau F; Chalayer E; De Broucker T; Hamidou M; Hunault M; Lyoubi A; Meunier R; Muron T; Sène D; Slama B; Guidoux C; Lefèvre G; Kahn JE; Denier C; Rohmer J
Stroke; 2021 Oct; 52(10):e605-e609. PubMed ID: 34304603
[TBL] [Abstract][Full Text] [Related]
2. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
3. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S
Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910
[No Abstract] [Full Text] [Related]
4. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
Ng HJ; Tan DC; Yiu RC; How GF
Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
[TBL] [Abstract][Full Text] [Related]
6. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
[TBL] [Abstract][Full Text] [Related]
8. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
9. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
10. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Arai A; Yan W; Wakabayashi S; Hayashi S; Inazawa J; Miura O
Int J Hematol; 2007 Oct; 86(3):233-7. PubMed ID: 17988989
[TBL] [Abstract][Full Text] [Related]
11. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
12. Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.
Kim DS; Lee S; Choi CW
Korean J Intern Med; 2018 May; 33(3):642-644. PubMed ID: 28651427
[No Abstract] [Full Text] [Related]
13. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
14. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
[TBL] [Abstract][Full Text] [Related]
15. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
Pitini V; Sturniolo G; Cavallari V; Arrigo C
Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
[No Abstract] [Full Text] [Related]
16. Oral mucosal manifestations of chronic eosinophilic leukaemia with FIP1L1-PDGFRα.
Tsuda K; Tanimoto T; Hayakawa K; Komatsu T
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26759442
[No Abstract] [Full Text] [Related]
17. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.
Qu SQ; Qin TJ; Xu ZF; Zhang Y; Ai XF; Li B; Zhang HL; Fang LW; Pan LJ; Hu NB; Xiao ZJ
Oncotarget; 2016 May; 7(22):33229-36. PubMed ID: 27120808
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
19. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
20. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
